SG10201809506TA - Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions - Google Patents

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Info

Publication number
SG10201809506TA
SG10201809506TA SG10201809506TA SG10201809506TA SG10201809506TA SG 10201809506T A SG10201809506T A SG 10201809506TA SG 10201809506T A SG10201809506T A SG 10201809506TA SG 10201809506T A SG10201809506T A SG 10201809506TA SG 10201809506T A SG10201809506T A SG 10201809506TA
Authority
SG
Singapore
Prior art keywords
ylmethyl
tetrahydro
quinoline
conditions
skin diseases
Prior art date
Application number
SG10201809506TA
Inventor
Mohammed I Dibas
Edward C Hsia
John E Donello
Daniel W Gil
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201809506T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of SG10201809506TA publication Critical patent/SG10201809506TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Pharmaceutical Compositions Comprising 7-(1H-lmidazol-4-Ylmethyl)-5, 6, 7, 8- Tetrahydro-Quinoline For Treating Skin Diseases And Conditions The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H- lmidazol-4-ylmethyl)-5,6,7,8-tetrahydro- quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof. Fig. 1
SG10201809506TA 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions SG10201809506TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10

Publications (1)

Publication Number Publication Date
SG10201809506TA true SG10201809506TA (en) 2018-11-29

Family

ID=47178364

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201809506TA SG10201809506TA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG11201402246RA SG11201402246RA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG10201609145PA SG10201609145PA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201402246RA SG11201402246RA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
SG10201609145PA SG10201609145PA (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Country Status (21)

Country Link
US (4) US20130123303A1 (en)
EP (3) EP3184110B1 (en)
JP (2) JP6359456B2 (en)
KR (1) KR102004563B1 (en)
CN (1) CN104136029A (en)
AR (1) AR088845A1 (en)
AU (2) AU2012335803B2 (en)
BR (1) BR112014011336A2 (en)
CA (1) CA2855005C (en)
CL (1) CL2014001242A1 (en)
DK (1) DK2776034T3 (en)
ES (1) ES2635421T3 (en)
IL (3) IL232483B (en)
MX (1) MX350662B (en)
MY (1) MY182553A (en)
RU (2) RU2667645C1 (en)
SG (3) SG10201809506TA (en)
TW (3) TW202014189A (en)
UA (1) UA109359C2 (en)
WO (1) WO2013070861A1 (en)
ZA (1) ZA201403396B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CN105188691A (en) * 2013-05-06 2015-12-23 阿勒根公司 Alpha adrenergic agonists for the treatment of tissue trauma
FR3061434B1 (en) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF PONGAMIA OIL AND PENTYLENE GLYCOL 4-T-BUTYLCYCLOHEXANOL FOR CONTROLLING ROSACEA
RU2727695C1 (en) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Method of complex treatment of rhinophyma

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676579B1 (en) * 1998-05-08 2008-12-31 The University Of Miami Use of sub-antimicrobial tetracyclines for treating ocular rosacea
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
WO2005051328A2 (en) * 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PL1761266T3 (en) * 2004-05-25 2013-09-30 Galderma Pharma Sa Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (en) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Method for treating patients for rosacea
US20090005450A1 (en) * 2007-04-09 2009-01-01 Belinda Tsao Nivaggioli Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8455548B2 (en) 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2010014552A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (en) * 2009-02-16 2010-08-20 Galderma Res & Dev ASSOCIATION OF COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DERMATOLOGICAL DISEASES
KR20120125230A (en) * 2009-10-26 2012-11-14 갈더마파마 에스.아. Methods of treating or preventing acute erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
ES2730411T3 (en) * 2010-03-26 2019-11-11 Galderma Res & Dev Enhanced compositions comprising brimonidine for a safe and effective treatment of telangiectasia
HUE033143T2 (en) * 2010-03-26 2017-11-28 Galderma Res & Dev Compositions comprising brimonidine for the treatment of erythema
US20130190317A1 (en) * 2010-08-06 2013-07-25 Galderma Research & Development Snc Combination of compounds for treating or preventing skin diseases

Also Published As

Publication number Publication date
IL268757A (en) 2019-10-31
US9308201B2 (en) 2016-04-12
WO2013070861A1 (en) 2013-05-16
EP2776034A1 (en) 2014-09-17
AU2012335803B2 (en) 2016-05-26
AU2012335803A1 (en) 2014-05-29
RU2014122758A (en) 2015-12-20
CA2855005C (en) 2016-11-22
US20170095466A1 (en) 2017-04-06
IL232483A0 (en) 2014-06-30
TW202014189A (en) 2020-04-16
SG11201402246RA (en) 2014-06-27
US20160051534A1 (en) 2016-02-25
AU2016216627B2 (en) 2017-10-19
EP2776034B1 (en) 2017-03-22
CN104136029A (en) 2014-11-05
TWI708604B (en) 2020-11-01
MX350662B (en) 2017-09-13
TW201328694A (en) 2013-07-16
RU2630978C2 (en) 2017-09-15
JP2017149767A (en) 2017-08-31
MX2014005640A (en) 2014-09-22
ES2635421T3 (en) 2017-10-03
ZA201403396B (en) 2015-07-29
EP3184110B1 (en) 2020-10-07
US20150231128A1 (en) 2015-08-20
IL261269A (en) 2018-10-31
SG10201609145PA (en) 2016-12-29
JP2014533271A (en) 2014-12-11
AR088845A1 (en) 2014-07-10
TWI580424B (en) 2017-05-01
IL232483B (en) 2018-10-31
NZ624771A (en) 2016-11-25
AU2016216627A1 (en) 2016-09-08
DK2776034T3 (en) 2017-07-10
UA109359C2 (en) 2015-08-10
KR20140107237A (en) 2014-09-04
EP3763370A1 (en) 2021-01-13
BR112014011336A2 (en) 2017-05-02
JP6526737B2 (en) 2019-06-05
US20130123303A1 (en) 2013-05-16
TW201713338A (en) 2017-04-16
RU2667645C1 (en) 2018-09-21
KR102004563B1 (en) 2019-07-26
JP6359456B2 (en) 2018-07-18
EP3184110A1 (en) 2017-06-28
MY182553A (en) 2021-01-25
CL2014001242A1 (en) 2014-11-14
CA2855005A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
MX2009010407A (en) Fluorinated derivatives of deferiprone.
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
MX2013012588A (en) Kinase inhibitors.
MX2015016425A (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
MX2011009709A (en) Compounds for treating inflammation and pain.
WO2013085849A3 (en) Sulfate esters of noribogaine
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
EA201290603A1 (en) METHOD OF TREATMENT
IL268757A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2013002208A (en) Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes.
MX2014014066A (en) Chromane compounds.
MX2013002956A (en) Arylosulfonamides for the treatment of cns diseases.
IN2013DN02555A (en)
MX2014014814A (en) Pharmaceutical composition for treating inflammation and pain.
MX348723B (en) Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder.
BR112014016450A2 (en) leukotriene b4 antagonist compound
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
MX2014011843A (en) Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma.
MX2014000870A (en) Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2- ylidene)-1h-benzimidazol-5-amine for treating retinal diseases.